Yong Liu, Dan Lu, Jie Sheng, Lijing Luo, Weiyuan Zhang
{"title":"Identification of TRADD as a potential biomarker in human uterine leiomyoma through iTRAQ based proteomic profiling","authors":"Yong Liu, Dan Lu, Jie Sheng, Lijing Luo, Weiyuan Zhang","doi":"10.1016/j.mcp.2017.07.001","DOIUrl":null,"url":null,"abstract":"<div><p><span>Recurrent and refractory leiomyoma of uterus is one of the most common diseases in women of reproductive age. Despite its benign nature, </span>uterine leiomyoma<span><span><span> has presented an extremely deleterious impact on public health<span>. The etiology of uterine leiomyoma remains unclear and clinical management remains suboptimal, leaving radical hysterectomy the only effective approach. Delineating the molecular mechanism underlying the leiomyoma initiation and progression remains an unmet clinical need. To screen proteins that were differentially expressed in uterine leiomyoma versus normal </span></span>myometrium<span>, we examined proteomic<span><span><span> profile by isobaric tag for relative and absolute quantitation (iTRAQ) labeling coupled with liquid chromatography - tandem mass spectrometry (LC-MS/MS). 72 proteins have been identified as differentially expressed in uterine leiomyoma, including the downregulation of </span>TRADD (tumor necrosis factor receptor type 1-associated DEATH domain protein), which dominates the dysfunctional extrinsic </span>apoptosis<span> pathway and deregulated inflammatory responses. The reduction of TRADD was further validated by Western blot and </span></span></span></span>immunohistochemistry in independent sample cohorts. Our data thus suggest potential biological significance of TRADD mediated inflammatory response in the development of uterine leiomyoma.</span></p></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":"36 ","pages":"Pages 15-20"},"PeriodicalIF":2.3000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.mcp.2017.07.001","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890850817300683","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 5
Abstract
Recurrent and refractory leiomyoma of uterus is one of the most common diseases in women of reproductive age. Despite its benign nature, uterine leiomyoma has presented an extremely deleterious impact on public health. The etiology of uterine leiomyoma remains unclear and clinical management remains suboptimal, leaving radical hysterectomy the only effective approach. Delineating the molecular mechanism underlying the leiomyoma initiation and progression remains an unmet clinical need. To screen proteins that were differentially expressed in uterine leiomyoma versus normal myometrium, we examined proteomic profile by isobaric tag for relative and absolute quantitation (iTRAQ) labeling coupled with liquid chromatography - tandem mass spectrometry (LC-MS/MS). 72 proteins have been identified as differentially expressed in uterine leiomyoma, including the downregulation of TRADD (tumor necrosis factor receptor type 1-associated DEATH domain protein), which dominates the dysfunctional extrinsic apoptosis pathway and deregulated inflammatory responses. The reduction of TRADD was further validated by Western blot and immunohistochemistry in independent sample cohorts. Our data thus suggest potential biological significance of TRADD mediated inflammatory response in the development of uterine leiomyoma.
期刊介绍:
MCP - Advancing biology through–omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.